Sign In
Buy CVAC
$4.66
+0 (+0%)
At Close: Apr 02, 2026
Top Stock Movers Now: Oracle, Boeing, CureVac, and More
12:05pm, Thursday, 12'th Jun 2025
U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow
CureVac Stock Soars on BioNTech Buyout
11:08am, Thursday, 12'th Jun 2025
Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
11:07am, Thursday, 12'th Jun 2025
BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.
BioNTech boosts cancer mRNA pipeline with CureVac acquisition
10:34am, Thursday, 12'th Jun 2025
BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms,
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
08:39am, Thursday, 12'th Jun 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the ter
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
07:11am, Thursday, 12'th Jun 2025
CureVac stock soared 29% $5.26 in premarket trading immediately following the news.
BioNTech to acquire CureVac in $1.25 billion all-stock deal
07:03am, Thursday, 12'th Jun 2025
German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
07:15am, Tuesday, 20'th May 2025
U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
04:45pm, Thursday, 15'th May 2025
European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendment
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
12:59pm, Thursday, 10'th Apr 2025
CureVac N.V. (NASDAQ:CVAC ) Q4 2024 Earnings Conference Call April 10, 2025 9:00 AM ET Company Participants Sarah Fakih - Vice President, Corporate Communications and Investor Relations Alexander Zehn
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
07:30am, Thursday, 10'th Apr 2025
Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precisi
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
07:25am, Tuesday, 08'th Apr 2025
TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic aci
Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC encodes nove
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
08:58am, Friday, 28'th Mar 2025
CureVac N.V. CVAC on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
European Patent Office declares CureVac mRNA patent valid
06:22pm, Thursday, 27'th Mar 2025
The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.
